Investors should skip buying Merck shares because of valuation and political risk, BMO Capital said. » Read More
Gilead Sciences lowered its full-year sales outlook, citing slower-than-expected demand for its hepatitis C drugs, and said profits fell 22 percent.
BERLIN— Germany's Ifo institute releases its monthly business confidence index, a key indicator for Europe's biggest economy. WASHINGTON— Standard& Poor's releases S&P/Case-Shiller index of home prices for May, 9 a.m.; The Conference Board releases the Consumer Confidence Index for July, 10 a.m.; Commerce Department releases new home sales for June, 10 a.m.;...
These are the stocks on the move ahead of the opening bell.
U.S. stocks closed higher Wednesday, helped by rising oil prices, and after the Fed released minutes from its June meeting.
U.S. stocks closed lower Wednesday, weighed by declines in energy stocks, as investors remained on edge ahead of the Brexit vote.
Inovio's Zika vaccine will be the 14th drug the company has in testing, but its CEO insisted Tuesday the company is not spread too thin.
U.S. stocks closed lower Friday, with health care and tech stocks lagging, amid continued uncertainty ahead of next week's scheduled Brexit vote.
Jim Cramer wasn't freaked out by this bold event in the oil patch.
U.S. stocks closed higher Thursday, ending a five-day losing streak with telecoms leading sector advancers.
CNBC's Jim Cramer explains why he is watching Merck and oil.
Moderna has been quietly developing its messenger RNA technology since 2010. Now the company is testing that knowledge in humans.
CNBC's Meg Tirrell talks with Merck's Roger Perlmutter about advances the drugmaker has made in treating cancer, including immunotherapy drug KEYTRUDA. Perlmutter also addresses concerns over the high price of drugs.
As the world's largest cancer research conference gets underway, here's how to play the stocks.
CNBC's Meg Tirrell reports on what bio-pharma breakthroughs to expect out of this year's ASCO conference, and the "FMHR" traders weigh in on the biotech sector.
Some of the names on the move ahead of the open.
Jim Cramer marked the anniversary of the market hitting an all-time high one year ago with an in-depth analysis of the Dow Jones.
U.S. stocks closed mixed in below average trade volume Monday, with gains in health care offsetting declines in materials and energy as oil fell.
U.S. stocks closed narrowly mixed Thursday as oil failed to hold much of its intraday gains and investors awaited the key employment report due Friday.
Discussing the impact of biotech deals on the sector overall, and whether Sanofi's offer for Medivation will pass, with Michael King, JMP Securities, and Les Funtleyder, E Squared Capital.
U.S. stock index futures were higher Thursday morning, helped by gains in oil prices as concerns of a near-term supply shortage rose.